- Home
- HSHP vs IRWD Comparison
HSHP vs IRWD Comparison
Compare HSHP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- IRWD
- Stock Information
- Founded
- HSHP 2021
- IRWD 1998
- Country
- HSHP Bermuda
- IRWD United States
- Employees
- HSHP N/A
- IRWD N/A
- Industry
- HSHP
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- IRWD Health Care
- Exchange
- HSHP Nasdaq
- IRWD Nasdaq
- Market Cap
- HSHP 268.6M
- IRWD 251.8M
- IPO Year
- HSHP 2023
- IRWD 2010
- Fundamental
- Price
- HSHP $8.14
- IRWD $1.43
- Analyst Decision
- HSHP
- IRWD Buy
- Analyst Count
- HSHP 0
- IRWD 5
- Target Price
- HSHP N/A
- IRWD $4.94
- AVG Volume (30 Days)
- HSHP 151.6K
- IRWD 1.2M
- Earning Date
- HSHP 11-20-2025
- IRWD 11-06-2025
- Dividend Yield
- HSHP 5.54%
- IRWD N/A
- EPS Growth
- HSHP N/A
- IRWD N/A
- EPS
- HSHP 0.14
- IRWD N/A
- Revenue
- HSHP $120,680,000.00
- IRWD $308,519,000.00
- Revenue This Year
- HSHP $9.48
- IRWD N/A
- Revenue Next Year
- HSHP $31.39
- IRWD N/A
- P/E Ratio
- HSHP $59.18
- IRWD N/A
- Revenue Growth
- HSHP 44.77
- IRWD N/A
- 52 Week Low
- HSHP $4.29
- IRWD $0.53
- 52 Week High
- HSHP $8.95
- IRWD $5.13
- Technical
- Relative Strength Index (RSI)
- HSHP 50.09
- IRWD 51.44
- Support Level
- HSHP $7.81
- IRWD $1.41
- Resistance Level
- HSHP $8.23
- IRWD $1.71
- Average True Range (ATR)
- HSHP 0.18
- IRWD 0.17
- MACD
- HSHP -0.04
- IRWD -0.01
- Stochastic Oscillator
- HSHP 56.94
- IRWD 27.69
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.